Federal contractor · public award history
CROSSJECT SA
Parent: CROSSJECT SA Unique Entity Identifier (UEI)NLXZHCL3NLL3
- Awards we know about
- 1
- Typical size
- $104.15M
- Middle of their public awards
- Dollars on those awards
- $104.15M
Most of their awards we can see fall roughly between $104.15M and $104.15M.
SAM.gov registration
- Status
- Active
- Purpose of registration
- All awards (Z2)
- Registration expires
- Oct 9, 2026
- Activation date
- Oct 9, 2025
- Primary NAICS (SAM)
- Research and Development in Biotechnology (except Nanobiotechnology)541714
Other NAICS on file
Business types (SAM)
Registration fields from the official SAM.gov public entity extract (monthly bulk). Not a substitute for live SAM checks.
Continue contractor research
Use the verified identifiers and public award record to investigate documented incumbents, compare competitors, or identify possible teaming partners. This is a research starting point, not a capability or partner recommendation.
These official USAspending contract records do not rate capability or past performance and do not tell you whether to team or bid.
Awarding agencies
- Department of Health and Human Services (1)
Industries & product codes
Award history
- Department of Health and Human Services$104.15MSep 16, 2025Procurement Instrument Identifier (PIID)75A50122C00031Research and Development in Biotechnology (except Nanobiotechnology)541714Health R&D Services; Health Care Services; Experimental DevelopmentAN13Contract awardUSAspending ↗
ADVANCED RESEARCH AND DEVELOPMENT AND DELIVERY OF ADULT AND PEDIATRIC MIDAZOLAM AUTOINJECTORS THAT HAVE RECEIVED EMERGENCY USE AUTHORIZATION (EUA) OR FDA APPROVAL FOR THE TREATMENT OF STATUS EPILEPTICUS SEIZURES IN ADULT AND PEDIATRIC POPULATIONS (2+
For research only. This is not legal advice, a past-performance review, or a recommendation to team or bid. Check USAspending and SAM.gov.